An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment.
- Author:
Tae Geun GWEON
1
;
Joon Sung KIM
;
Byung Wook KIM
Author Information
- Publication Type:Original Article
- Keywords: Helicobacter pylori; Clarithromycin; Polymerase chain reaction; Cost
- MeSH: Breath Tests; Clarithromycin; Diagnostic Tests, Routine; Helicobacter pylori*; Helicobacter*; Humans; Medical Records; Models, Economic*; Multiplex Polymerase Chain Reaction*; Polymerase Chain Reaction
- From:Gut and Liver 2018;12(6):648-654
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Dual priming oligonucleotide-based multiplex polymerase chain reaction (DPO-based PCR) can detect the presence of clarithromycin resistance without culture. The aim of this study was to investigate the cost-effectiveness of DPO-based PCR for Helicobacter pylori eradication. METHODS: From 2015 to 2016, medical records of patients who received H. pylori eradication therapy were analyzed. Patients were divided into two groups: tailored group patients who were treated based on DPO-based PCR and empirical group patients. Eradication rate and medical cost, including diagnostic tests, eradication regimens, and 13C-urea breath tests, were compared between the two groups. Cost for one successful eradication was calculated in each group. The expected cost of eradication for empirical treatment was investigated by varying the treatment duration and eradication rate. RESULTS: A total of 527 patients were analyzed (tailored group 208, empirical group 319). The eradication success rate of the first-line therapy was higher in the tailored group compared to that in the empirical group (91.8% vs 72.1%, p < 0.01). The total medical cost for each group was 114.8±14.1 U.S. dollars (USD) and 85.8±24.4 USD, respectively (p < 0.01). The total medical costs for each ultimately successful eradication in the tailored group and in the empirical group were 120.0 USD and 92.4 USD, respectively. The economic modeling expected cost of a successful eradication after a 7- or 14-day empirical treatment was 93.8 to 111.4 USD and 126.3 to 149.9 USD, respectively. CONCLUSIONS: Based on economic modeling, the cost for a successful eradication using DPO-based PCR would be similar or superior to the expected cost of a successful eradication with a 14-day empirical treatment when the first-line eradication rate is 80%.
